AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24794721
Drug: Subcutaneous peginterferon
RxNorm normalized name: peginterferon alfa-2a Injection [Pegasys]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous peginterferon beta‐1a 125 μg every 2 weeks
Trial: 24794721
Drug: Subcutaneous peginterferon
RxNorm normalized name: peginterferon alfa-2a Injection [Pegasys]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous peginterferon beta‐1a 125 μg every 4 weeks
Trial: 20484128
Drug: Letrozole (aromatase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole (aromatase inhibitor) to lower estradiol and increase testosterone (group T)
Trial: 20484128
Drug: Letrozole plus
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole plus E(2) patches to lower testosterone and raise estradiol (group E)
Trial: 12027070
Drug: 100 microg
RxNorm normalized name: Digoxin 100 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 microg albuterol/HFA 134a
Trial: 12027070
Drug: 200 microg
RxNorm normalized name: Digoxin 200 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 microg albuterol/HFA 134a
Trial: 12027070
Drug: 400 microg
RxNorm normalized name: Fentanyl 400 microgram buccal film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 microg albuterol/HFA 134a
Trial: 12027070
Drug: 100 microg
RxNorm normalized name: Digoxin 100 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 microg albuterol/CFC
Trial: 12027070
Drug: 200 microg
RxNorm normalized name: Digoxin 200 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 microg albuterol/CFC
Trial: 6682667
Drug: Maalox 70
RxNorm normalized name: Maalox
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maalox 70 (4 x 10 ml/die)
Trial: 26011779
Drug: Armodafinil (150‐250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Armodafinil (150‐250 mg/day)
Trial: 23230975
Drug: everolimus <3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: everolimus <3 ng/mL
Trial: 23230975
Drug: everolimus ≥
FDA approved: no
EMA approved: no
PMDA approved: no
Description: everolimus ≥ 12 ng/mL
Trial: 23230975
Drug: everolimus 3-8
RxNorm normalized name: everolimus 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: everolimus 3-8 ng/mL and CsA <100 ng/mL
Trial: 22105589
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of modafinil (3 doses, given 8 hourly)
Trial: 22105589
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of modafinil (3 doses, given 8 hourly)
Trial: 22105589
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of modafinil (2 doses) plus placebo (1 dose, given 8 hourly)
Trial: 22105589
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 doses, given 8 hourly)
Trial: 19761889
Drug: Mashed potato
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mashed potato with HV‐HPMC (all doses)
Trial: 19761889
Drug: HV‐HPMC doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HV‐HPMC doses
Trial: 11834140
Drug: Glycyrrhetinic acid
RxNorm normalized name: Glycyrrhetinic Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycyrrhetinic acid (GA) 500 mg
Trial: 20576419
Drug: Mannitol 240
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mannitol 240 mg
Trial: 20576419
Drug: Mannitol 480
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mannitol 480 mg
Trial: 17591126
Drug: Propofol administration
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol administration with bispectral index monitoring (group B)
Trial: 12453546
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg oral morphine four times daily for 4 days (2.5 mg if creatinine > 200 micromol/l)
Trial: 7793547
Drug: Diamorphine at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diamorphine at highest dose (533 micrograms.h‐1)
Trial: 1822492
Drug: Intracervical dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intracervical dinoprostone 0.5 mg gel (Group 1, n = 24)
Trial: 1822492
Drug: Intracervical administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracervical administration of PGE2 1.5 mg on Surgicel (Group 2, n = 26)
Trial: 1822492
Drug: Intracervical dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intracervical dinoprostone 0.5 mg gel (Group 3, n = 28)
Trial: 1822492
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of PGE2 2.25 mg on a Spongel (Group 4, n = 22)
Trial: 31498469
Drug: Testosterone therapy
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone therapy (TTh) injections (>12 injections)
Trial: 31498469
Drug: Testosterone therapy
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone therapy (TTh) topical gels (>330 days supply)
Trial: 31498469
Drug: Testosterone therapy
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone therapy (injection and gel) in nondiabetics
Trial: 31498469
Drug: Testosterone therapy
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone therapy injections in diabetics
Trial: 29800370
Drug: Live-attenuated tetravalent
RxNorm normalized name: varicella, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live-attenuated tetravalent dengue vaccine (TDV)
Trial: 27790333
Drug: Lactocare® (Synbiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactocare® (Synbiotic containing 1 billion CFU/Capsule of various probiotics)
Trial: 19556719
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg aspirin + 300 mg rebamipide
Trial: 19556719
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg aspirin + placebo
Trial: 17886708
Drug: Alternant chemotherapy
RxNorm normalized name: Alternanthera sessilis extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternant chemotherapy
Trial: 17886708
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy with hematologic support
Trial: 17886708
Drug: New targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New targeted therapy agents or immunotherapeutic approaches
Trial: 15793155
Drug: Oral doxycycline
RxNorm normalized name: doxycycline Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral doxycycline at 200 mg every 24 h
Trial: 2194047
Drug: Progesterone 400
RxNorm normalized name: progesterone 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progesterone 400 mg
Trial: 2194047
Drug: Progesterone 800
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Progesterone 800 mg
Trial: 369623
Drug: L-5-hydroxytryptophan (L-5HTP)
RxNorm normalized name: L-5-HTP
DrugBank: Oxitriptan (DB02959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-5-hydroxytryptophan (L-5HTP) with carbidopa
Trial: 25265255
Drug: Tacrolimus once-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus once-daily formulation (Tac-OD)
Trial: 25265255
Drug: Tacrolimus twice-daily
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus twice-daily formulation (Tac-TD)
Trial: 21366473
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy (targeting a glycated hemoglobin level below 6.0%)
Trial: 21366473
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (targeting a glycated hemoglobin level of 7 to 7.9%)
Trial: 18298579
Drug: Didanosine enteric-coated
RxNorm normalized name: didanosine
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Didanosine enteric-coated capsules (ddI-EC) administered in a fasted state (group 1)
Trial: 18298579
Drug: Didanosine enteric-coated
RxNorm normalized name: didanosine
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Didanosine enteric-coated capsules (ddI-EC) administered with food (group 2)
Trial: 10918483
Drug: DNA/liposome formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNA/liposome formulation (plasmid DNA expressing CFTR cDNA complexed with DC‐Chol/DOPE cationic liposomes)
Trial: 9005590
Drug: Mepartricin 150,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepartricin 150,000 U (40 mg) administered once-a-day in the evening for 60 days
Trial: 1419290
Drug: 3M (mitozantrone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3M (mitozantrone 6.5 mg/m2 q 21 days, methotrexate 30 mg/m2 q 21 days, mitomycin C 6.5 mg/m2 q 42 days)
Trial: 31370792
Drug: Multi-component intervention
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-component intervention A (advanced) including nutritional counseling, physical activity, cognitive training, optimization of medication, management of vascular risk factors, social activity, and specific interventions targeting grief and depression
Trial: 31370792
Drug: General health
RxNorm normalized name: Walgreens Men-General Health Multivitamin Gummies Soft Chew
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General health advice and GP treatment as usual (Intervention B)
Trial: 21482863
Drug: Becaplermin gel
RxNorm normalized name: becaplermin Topical Gel
DrugBank: Becaplermin (DB00102)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Becaplermin gel (0.1% in hydrogel), applied once daily for 8 weeks
Trial: 21482863
Drug: Hydrogel dressing,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrogel dressing, applied once daily for 8 weeks
Trial: 21482863
Drug: Becaplermin gel
RxNorm normalized name: becaplermin Topical Gel
DrugBank: Becaplermin (DB00102)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Becaplermin gel and Hydrogel dressing
Trial: 19917839
Drug: Trastuzumab (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab (6 mg/kg every 3 weeks for 1 year)
Trial: 12644426
Drug: Continuous i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous i.v. diltiazem 1 micro g kg(‐1) min(‐1)
Trial: 10709897
Drug: Fluid regime
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid regime A (60 ml/kg on day 1, increasing to 150 ml/kg over the first week)
Trial: 7529606
Drug: G‐CSF and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF and GM‐CSF
Trial: 3395027
Drug: Cefamandole 1-gram
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefamandole 1-gram preoperative dose followed by 4 additional postoperative doses at 6-hour intervals
Trial: 3395027
Drug: Cefamandole 2-gram
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefamandole 2-gram doses
Trial: 3395027
Drug: Cefoxitin 2-gram
RxNorm normalized name: cefoxitin
DrugBank: Cefoxitin (DB01331)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefoxitin 2-gram doses
Trial: 30016417
Drug: Passive air-suspension
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive air-suspension seat (control)
Trial: 28672073
Drug: Exercise intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exercise intervention (two doses for 12 weeks)
Trial: 18922988
Drug: High hemoglobin
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High hemoglobin target (13.5 to 14.5 g/dl)
Trial: 10507244
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg benfotiamin (S-benzoylthiamine-o-monophosphate, BTMP)
Trial: 10507244
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg thiamine mononitrate (TN)
Trial: 8251730
Drug: Youjiangzhi capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Youjiangzhi capsule
Trial: 3798932
Drug: Cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 400 mg i.v. t.i.d.
Trial: 3798932
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg i.v. b.i.d.
Trial: 30132960
Drug: Curcuminoids nanomicelles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcuminoids nanomicelles (80 mg, three times daily, orally) plus mesalamine (3 g/24 hours, orally)
Trial: 30132960
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus mesalamine (3 g/24 hours, orally)
Trial: 20567009
Drug: Oral bisphosphonates
RxNorm normalized name: methylene diphosphonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bisphosphonates (90% alendronate, 10% etidronate)
Trial: 18519002
Drug: Celecoxib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (400 mg one hour before surgery, then 200 mg every 12 hours for five days)
Trial: 18519002
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (only PCA morphine)
Trial: 12502022
Drug: YKP10A 400-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YKP10A 400-600 mg/day
Trial: 12502022
Drug: YKP10A 100-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YKP10A 100-300 mg/day
Trial: 12502022
Drug: YKP10A 700-900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YKP10A 700-900 mg/day
Trial: 4028514
Drug: Low alcohol
RxNorm normalized name: Low alcohol beer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low alcohol content beer (reduced from 336.3 ml to 64.5 ml ethanol/week)
Trial: 29529146
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g milk protein beverage containing 4.2 g leucine (LEU)
Trial: 29529146
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g mixed protein (milk and soy) beverage containing 1.3 g leucine (CON)
Trial: 27549509
Drug: Thoracic radiotherapy
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic radiotherapy (TRT) of 45 Gy/30 fractions (twice daily) plus standard chemotherapy (cisplatin/etoposide)
Trial: 27549509
Drug: Thoracic radiotherapy
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic radiotherapy (TRT) of 42 Gy/15 fractions (once daily) plus standard chemotherapy (cisplatin/etoposide)
Trial: 15978764
Drug: Low-dose CT
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CT (50 mAs)
Trial: 15978764
Drug: Standard-dose CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose CT (100 mAs)
Trial: 8566681
Drug: Bismuth subcitrate,
RxNorm normalized name: bismuth subcitrate, tetracycline and metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth subcitrate, metronidazole and amoxicillin (TG) for two weeks
Trial: 6248221
Drug: Cefoperazone (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoperazone (2.0 gm IV infusion over 30 minutes)
Trial: 6248221
Drug: Cefotaxime (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime (2.0 gm IV infusion over 30 minutes)
Trial: 21500992
Drug: Cetrorelix 0.25
RxNorm normalized name: cetrorelix 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetrorelix 0.25 mg/day
Trial: 21500992
Drug: Cetrorelix 0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetrorelix 0.125 mg/day
Trial: 9683360
Drug: Hyperfractionated radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperfractionated radiotherapy (two daily irradiations of 1.15 Gy up to 80.5 Gy in 7 weeks)
Trial: 2654256
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with cat-hair and dander extract (11 patients)
Trial: 29845905
Drug: Bedtime milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedtime milk snack with 10 g protein (BS10)
Trial: 29845905
Drug: Bedtime milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedtime milk snack with 30 g protein (BS30)
Trial: 23778157
Drug: Carbamazepine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine (600 mg)
Trial: 23778157
Drug: Lacosamide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacosamide (200 mg)
Trial: 23778157
Drug: Lacosamide (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacosamide (400 mg)
Trial: 16631435
Drug: Ezetimibe (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe (10 mg/d for 5 weeks)
Trial: 8985764
Drug: Perioperative nasal
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative nasal application of mupirocin calcium ointment, started on the day before surgery, continued for 5 days, twice daily
Trial: 8985764
Drug: Perioperative nasal
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative nasal application of mupirocin calcium ointment
Trial: 4053509
Drug: Baroreceptor stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baroreceptor stimulation and deactivation by injection of phenylephrine and trinitroglycerine
Trial: 29931179
Drug: Intramuscular hydroxocobalamin
RxNorm normalized name: Hydroxocobalamin
DrugBank: Hydroxocobalamin (DB00200)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular hydroxocobalamin injections (2000 µg loading dose, 1000 µg at follow-up) for 6 months
Trial: 29931179
Drug: Oral methylcobalamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral methylcobalamin (1000 µg daily) for 6 months
Trial: 29931179
Drug: Intramuscular hydroxocobalamin
RxNorm normalized name: Hydroxocobalamin
DrugBank: Hydroxocobalamin (DB00200)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular hydroxocobalamin injections
Trial: 29931179
Drug: Oral methylcobalamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral methylcobalamin
Trial: 27136318
Drug: Carboplatin monotherapy
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin monotherapy
Trial: 19363162
Drug: Discussion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discussion of substance use (smoking, alcohol, drug use)
Trial: 19363162
Drug: Discussion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discussion of smoking and drug use
Trial: 15752943
Drug: Nebivolol (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol (2.5 to 5.0 mg/day)
Trial: 15752943
Drug: Telmisartan (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan (40 to 80 mg/day)
Trial: 1758240
Drug: Succinylcholine 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine 0.4 mg/kg
Trial: 1758240
Drug: Succinylcholine 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine 0.6 mg/kg
Trial: 1758240
Drug: Succinylcholine 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine 0.8 mg/kg
Trial: 1758240
Drug: Succinylcholine 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine 1.2 mg/kg
Trial: 6278919
Drug: 475 mg
RxNorm normalized name: niacin 475 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 475 mg iodized oil by mouth
Trial: 21839625
Drug: Ciclesonide 40
RxNorm normalized name: Ciclesonide 400 microgram and formoterol fumarate dihydrate 12 microgram and tiotropium (as tiotropium bromide) 18 microgram/actuation powder for inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclesonide 40 μg
Trial: 20082586
Drug: Repaglinide (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repaglinide (2 mg)
Trial: 9681667
Drug: Eptastigmine without
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eptastigmine without food (30 mg)
Trial: 9681667
Drug: Eptastigmine with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eptastigmine with food (30 mg)
Trial: 8006396
Drug: 1.5 MU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 MU recombinant interferon alpha 2b (Intron) after steroid withdrawal
Trial: 2573379
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg tertatolol (T) once daily for one year
Trial: 2573379
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy (T + D)
Trial: 798469
Drug: Clopimozide, 24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopimozide, 24 mg weekly (Study I)
Trial: 798469
Drug: Clopimozide, daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopimozide, daily mean dose of 2.5 mg (Study III)